Passage Bio (id:8415 PASG)
0.505 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:11:16 PM)
Exchange closed, opens in 12 hours 18 minutes
About Passage Bio
Market Capitalization 36.46M
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
| Headquarters (address) |
One Commerce Square Philadelphia 19103 PA United States |
| Phone | 267 866 0311 |
| Website | https://www.passagebio.com |
| Employees | 58 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | PASG |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.451 - 1.79 |
| Market Capitalization | 36.46M |
| P/E trailing | -0.272 |
| P/E forward | -1.18 |
| Price/Book | 0.403 |
| Beta | 1.20 |
| EPS | -1.35 |
| EPS United States (ID:6, base:3402) | 24.23 |